Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 13, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Gene expression-based risk score in diffuse large B-cell lymphoma.

Caroline Bret1, Bernard Klein, Jérôme Moreaux

  • 1Department of Biological Hematology, St Eloi Hospital, Montpellier, France.

Oncotarget
|March 14, 2013
PubMed
Summary

A new 12-gene expression-based risk score (GERS) predicts survival in diffuse large B-cell lymphoma (DLBCL) patients. This GERS tool identifies high-risk individuals and improves prognostic classification when combined with the International Prognostic Index (IPI).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1.

American journal of hematology·2026
Same author

A non-catalytic function for RAD18 in sustaining glioblastoma proliferation.

Cell reports·2026
Same author

Single-nuclei UPR profiling by flow cytometry reveals bortezomib resistance mechanisms in multiple myeloma.

EMBO molecular medicine·2026
Same author

Inhibition of SUV39H1 as a potent therapeutic target in multiple myeloma.

Haematologica·2026
Same author

Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin-degrading enzyme, a new molecular vulnerability in multiple myeloma.

British journal of pharmacology·2026
Same author

Infectious Complications in Children, Adolescents, and Young Adults Treated for Acute Leukemia and Lymphoblastic Lymphoma: A Single-Center Experience.

Journal of pediatric hematology/oncology·2026

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is the most prevalent form of non-Hodgkin lymphoma, characterized by significant clinical and molecular heterogeneity.
  • Existing prognostic factors, such as the International Prognostic Index (IPI), do not fully capture the survival variability in DLBCL patients.

Purpose of the Study:

  • To develop and validate a novel gene expression-based risk score (GERS) for predicting overall survival in DLBCL patients.
  • To assess the independent prognostic value of GERS compared to established factors like IPI.
  • To investigate the utility of GERS across different molecular subtypes and treatment regimens.

Main Methods:

  • High-throughput gene expression profiling of DLBCL tumor samples.
  • Development of a 12-gene expression-based risk score (GERS).

More Related Videos

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)

Published on: August 21, 2016

Related Experiment Videos

Last Updated: May 13, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)

Published on: August 21, 2016

  • Validation of GERS in two independent patient cohorts (n=414 and n=69).

    • Main Results:

    • GERS identified a high-risk group comprising 46.4% of DLBCL patients across both cohorts.
    • GERS demonstrated independent prognostic value, outperforming the International Prognostic Index (IPI).
    • GERS maintained prognostic significance in germinal-center B-cell-like (GCB) and activated B cell-like (ABC) subtypes, and with CHOP/R-CHOP treatments.
    • Combining GERS with IPI resulted in a more potent prognostic classification.
    • Genomic instability signatures were identified in high-risk GERS-defined patients.

    Conclusions:

    • The 12-gene expression-based risk score (GERS) is a robust predictor of overall survival in DLBCL.
    • GERS offers improved prognostic stratification, particularly when integrated with the IPI.
    • GERS has potential applications in personalizing treatment strategies for DLBCL patients.